Anadys Raises $25M

Luke Timmerman10/15/10

Anadys Pharmaceuticals (NASDAQ: ANDS), the San Diego-based developer of a treatment for hepatitis C, said today it has raised about $25 million through a stock offering. The company sold about 13.9 million shares at $1.80 apiece. Lazard Capital Markets managed the deal.

Luke Timmerman is the National Biotech Editor of Xconomy. E-mail him at ltimmerman@xconomy.com Follow @